Phase I dose-escalation trial of Sym004, an anti-EGFR antibody mixture, in Japanese patients with advanced solid tumors

Takashi Kojima, Kentaro Yamazaki, Ken Kato, Kei Muro, Hiroki Hara, Keisho Chin, Thomas Goddemeier, Stefan Kuffel, Morihiro Watanabe, Toshihiko Doi, Takashi Kojima, Kentaro Yamazaki, Ken Kato, Kei Muro, Hiroki Hara, Keisho Chin, Thomas Goddemeier, Stefan Kuffel, Morihiro Watanabe, Toshihiko Doi

Abstract

Sym004 is a 1:1 mixture of two antibodies targeting non-overlapping epitopes of the epidermal growth factor receptor that antagonizes ligand binding and induces receptor downregulation. In preclinical models, it has superior antitumor activity to cetuximab and panitumumab. Japanese adults aged ≥20 years with an Eastern Cooperative Oncology Group status of 0/1 and life expectancy ≥3 months were eligible. Patients in Part A (dose escalation) had refractory or recurrent late-stage solid tumors and received Sym004 6 mg/kg/wk (n = 3), 9 mg/kg loading/6 mg/kg/wk (n = 6), 12 mg/kg/wk (n = 6), or 18 mg/kg biweekly (n = 6). Patients in expansion Part B (n = 30) had esophageal squamous cell carcinoma and received Sym004 at the dose recommended from Part A. Fifty-one patients received Sym004. No dose-limiting toxicities were observed in Part A. A dose of 12 mg/kg/wk was selected for Part B. All patients in Part B experienced treatment-related adverse events, most commonly dermatitis acneiform (76.7%). Eighteen grade ≥3 treatment-related adverse events and five serious adverse events occurred (cardiac arrest, lung infection, interstitial lung disease, toxic skin eruption, blood creatinine increase). Two patients had treatment-related adverse events resulting in death (cardiac arrest and blood creatinine increase). Five patients in Part B had a best overall response of partial response, 12 stable diseases and 12 disease progression (1 not evaluable). The objective response rate was 16.7% (95% CI: 5.6%-34.7%). Sym004 therapy was well tolerated with no dose-limiting toxicities at any dose studied. Evidence of antitumor activity was seen in patients with esophageal squamous cell carcinoma. ClinicalTrials.gov Identifier: NCT01955473.

Keywords: EGFR; Sym004; antibody; solid tumors; therapy.

© 2018 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

Figures

Figure 1
Figure 1
Response to Sym004 therapy of patients in Part B of the trial. (A) Swimmer plot and (B) waterfall plot. NE, not evaluated; PD, progressive disease; PR, partial response; SD, stable disease
Figure 2
Figure 2
Mean (±SD) serum concentration‐time profiles for mAb1024 and mAb992 after (A) the 1st (wk 1) and 4th (wk 4) weekly infusions and (B) the 1st (wk 1) and 3rd (wk 5) weekly infusions (semilogarithmic scale)

References

    1. Kothari N, Almhanna K. Current status of novel agents in advanced gastroesophageal adenocarcinoma. J Gastrointest Oncol. 2015;6:60‐74.
    1. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol. 2003;21:2787‐2799.
    1. Sawada G, Niida A, Hirata H, et al. An integrative analysis to identify driver genes in esophageal squamous cell carcinoma. PLoS ONE. 2015;10:e0139808.
    1. Jiang D, Li X, Wang H, et al. The prognostic value of EGFR overexpression and amplification in esophageal squamous cell carcinoma. BMC Cancer. 2015;15:377.
    1. Kaneko K, Kumekawa Y, Makino R, et al. EGFR gene alterations as a prognostic biomarker in advanced esophageal squamous cell carcinoma. Front Biosci (Landmark Ed). 2010;15:65‐72.
    1. Lin G, Sun XJ, Han QB, et al. Epidermal growth factor receptor protein overexpression and gene amplification are associated with aggressive biological behaviors of esophageal squamous cell carcinoma. Oncol Lett. 2015;10:901‐906.
    1. Hanawa M, Suzuki S, Dobashi Y, et al. EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int J Cancer. 2006;118:1173‐1180.
    1. Jia J, Cui Y, Lu M, et al. The relation of EGFR expression by immunohistochemical staining and clinical response of combination treatment of nimotuzumab and chemotherapy in esophageal squamous cell carcinoma. Clin Transl Oncol. 2016;18:592‐598.
    1. Li JC, Zhao YH, Wang XY, et al. Clinical significance of the expression of EGFR signaling pathway‐related proteins in esophageal squamous cell carcinoma. Tumour Biol. 2014;35:651‐657.
    1. Yang YL, Xu KL, Zhou Y, Gao X, Chen LR. Correlation of epidermal growth factor receptor overexpression with increased epidermal growth factor receptor gene copy number in esophageal squamous cell carcinomas. Chin Med J (Engl). 2012;125:450‐454.
    1. FDA . FDA Approval for cetuximab. . Accessed July 1, 2018.
    1. FDA . FDA approval for panitumumab. . Accessed July 1, 2018.
    1. Li S, Schmitz KR, Jeffrey PD, et al. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell. 2005;7:301‐311.
    1. Cohenuram M, Saif MW. Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anticancer Drugs. 2007;18:7‐15.
    1. Kawaguchi Y, Kono K, Mimura K, et al. Cetuximab induce antibody‐dependent cellular cytotoxicity against EGFR‐expressing esophageal squamous cell carcinoma. Int J Cancer. 2007;120:781‐787.
    1. Koefoed K, Steinaa L, Soderberg JN, et al. Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor. MAbs. 2011;3:584‐595.
    1. Dienstmann R, Salazar R, Tabernero J. Overcoming resistance to anti‐EGFR therapy in colorectal cancer. Am Soc Clin Oncol Educ Book. 2015:e149‐e156. . Accessed July 1, 2018.
    1. Pedersen MW, Jacobsen HJ, Koefoed K, et al. Sym004: a novel synergistic anti‐epidermal growth factor receptor antibody mixture with superior anticancer efficacy. Cancer Res. 2010;70:588‐597.
    1. Iida M, Brand TM, Starr MM, et al. Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab. Neoplasia. 2013;15:1196‐1206.
    1. Sanchez‐Martin FJ, Bellosillo B, Gelabert M, et al. The first‐in‐class anti‐EGFR antibody mixture Sym004 overcomes cetuximab‐resistance mediated by EGFR extracellular domain mutations in colorectal cancer. Clin Cancer Res. 2016;22(13):3260‐3267.
    1. Machiels JP, Specenier P, Krauss J, et al. A proof of concept trial of the anti‐EGFR antibody mixture Sym004 in patients with squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol. 2015;76:13‐20.
    1. Dienstmann R, Patnaik A, Garcia‐Carbonero R, et al. Safety and activity of the first‐in‐class Sym004 anti‐EGFR antibody mixture in patients with refractory colorectal cancer. Cancer Discov. 2015;5:598‐609.
    1. Kozuki T. Skin problems and EGFR‐tyrosine kinase inhibitor. Jpn J Clin Oncol. 2016;46:291‐298.
    1. Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Barni S. Risk of anti‐EGFR monoclonal antibody‐related hypomagnesemia: systematic review and pooled analysis of randomized studies. Expert Opin Drug Saf. 2012;11(Suppl 1):S9‐S19.
    1. FDA . Erbitux® Prescribing Information. . Accessed July 1, 2018.
    1. Fukuoka S, Kojima T, Koga Y, et al. Preclinical efficacy of Sym004, novel anti‐EGFR antibody mixture, in esophageal squamous cell carcinoma cell lines. Oncotarget. 2017;8:11020‐11029.
    1. Guo K, Wang WP, Jiang T, et al. Assessment of epidermal growth factor receptor mutation/copy number and K‐ras mutation in esophageal cancer. J Thorac Dis. 2016;8:1753‐1763.
    1. Sunpaweravong P, Suwiwat S, Sunpaweravong S, Puttawibul P, Mitarnun W. Correlation of epidermal growth factor receptor mutation, immunohistochemistry, and fluorescence in situ hybridization in esophageal squamous cell carcinoma. J Med Assoc Thai. 2009;92:1136‐1142.
    1. Dienstmann R, Salazar R, Tabernero J. The evolution of our molecular understanding of colorectal cancer: what we are doing now, what the future holds, and how tumor profiling is just the beginning. Am Soc Clin Oncol Educ Book. 2014:91‐99. . Accessed July 1, 2018.
    1. Wu X, Zhang J, Zhen R, et al. Trastuzumab anti‐tumor efficacy in patient‐derived esophageal squamous cell carcinoma xenograft (PDECX) mouse models. J Transl Med. 2012;10:180.
    1. Mimura K, Kono K, Maruyama T, et al. Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody‐dependent cellular cytotoxicity of EGFR‐ and HER2‐overexpressing esophageal cancer cell lines. Int J Cancer. 2011;129:2408‐2416.
    1. Sutter AP, Hopfner M, Huether A, Maaser K, Scherubl H. Targeting the epidermal growth factor receptor by Erlotinib (Tarceva) for the treatment of esophageal cancer. Int J Cancer. 2006;118:1814‐1822.
    1. Wang C, Fu X, Cai X, et al. High‐dose nimotuzumab improves the survival rate of esophageal cancer patients who underwent radiotherapy. Onco Targets Ther. 2016;9:117‐122.
    1. Chen Y, Wu X, Bu S, et al. Promising outcomes of definitive chemoradiation and cetuximab for patients with esophageal squamous cell carcinoma. Cancer Sci. 2012;103:1979‐1984.
    1. Dutton SJ, Ferry DR, Blazeby JM, et al. Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double‐blind, placebo‐controlled randomised trial. Lancet Oncol. 2014;15:894‐904.
    1. Crosby T, Hurt CN, Falk S, et al. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. Lancet Oncol. 2013;14:627‐637.
    1. Kudo T, Hamamoto Y, Kato K, et al. Nivolumab treatment for oesophageal squamous‐cell carcinoma: an open‐label, multicentre, phase 2 trial. Lancet Oncol. 2017;18:631‐639.
    1. Burkart C, Bokemeyer C, Klump B, et al. A phase II trial of weekly irinotecan in cisplatin‐refractory esophageal cancer. Anticancer Res. 2007;27:2845‐2848.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다